286 results on '"Bhatt, D. L."'
Search Results
2. Impact of the stepwise approach to cardiovascular disease prevention in patients with established ASCVD from the 2021 ESC Prevention Guideline
3. High-sensitivity troponin-T concentrations and long-term risk of death in patients with acute pulmonary embolism
4. Heart failure medical therapy and outcomes in patients undergoing transcatheter mitral valve repair for secondary mitral regurgitation: a TVT Registry analysis across 449 US centers
5. Serial high-sensitivity troponin-I and long-term risk of myocardial infarction and coronary revascularization in subjects with suspected acute coronary syndrome
6. Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
7. High-sensitivity troponin-i and risk of heart failure in individuals with suspected acute coronary syndrome
8. Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT
9. Glomerular filtration rate predicts pro-vascular progenitor cell depletion: insights from the IPE-PREVENTION and ORIGINS-RCE studies
10. Colchicine for cardiovacular risk reduction in lower extremity peripheral artery disease
11. Eicosapentaenoic acid (EPA) treatment increased the ratio to arachidonic (EPA/AA) and reduced adhesion molecule expression in vascular endothelium during inflammation
12. Eicosapentaenoic acid (EPA) reduced expression of neutrophil activation proteins in endothelial cells during challenge with angiotensin II (Ang II) and cytokines
13. Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome
14. Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS
15. Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial
16. Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking
17. Serial high-sensitivity troponin T concentrations and long-term outcomes in patients with suspected acute coronary syndrome
18. A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey
19. Supplement to: Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcome.
20. P1483: EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 FATTY ACID, PROTECTS HUMANIZED SICKLE CELL MICE AGAINST HYPOXIA/REOXYGENATION ORGAN DAMAGE
21. POS0519 RELATIONSHIP BETWEEN DISEASE ACTIVITY AND MAJOR ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TOFACITINIB OR TNF INHIBITORS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
22. POS0110 INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS STRATIFIED BY GEOGRAPHIC REGION AND BASELINE CARDIOVASCULAR RISK: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
23. POS0237 MAJOR ADVERSE CARDIOVASCULAR EVENTS, MALIGNANCIES AND VENOUS THROMBOEMBOLISM BY BASELINE CARDIOVASCULAR RISK: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
24. OP0264 IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
25. POS0520 ASSOCIATION BETWEEN BASELINE STATIN TREATMENT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
26. POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
27. Greater event rates in high-risk patients with a history of heart disease: from the Systolic Blood Pressure Intervention Trial (SPRINT)
28. Supplement to: Long-term use of ticagrelor in patients with prior myocardial infarction
29. Marital status, cardiovascular events, and intensive blood pressure lowering among men and women in the Systolic Blood Pressure Intervention Trial
30. Eicosapentaenoic acid inhibits lipopolysaccharide (LPS)-induced nitrite production and cytokine release from J774 macrophages
31. Greater event rates in high-risk patients with a history of heart disease: from the Systolic Blood Pressure Intervention Trial (SPRINT)
32. Omega-3 fatty acids differentially alter the expression of detoxification enzymes and nitric oxide bioavailability in endothelial cells during IL-6 exposure
33. Omega-3 fatty acids differentially reduced expression of neutrophil degranulation-associated proteins in endothelial cells during IL-6 exposure
34. Primary health insurance and cardiovascular outcomes in the systolic blood pressure intervention trial
35. Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy
36. Response to: ‘baseline differences in SAVOR trial’ – prespecified vs. post hoc analysis – a potential source of bias
37. Supplement to: Bariatric surgery versus intensive medical therapy for diabetes — 3-year outcomes.
38. Supplement to: A controlled trial of renal denervation for resistant hypertension.
39. The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial
40. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study
41. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
42. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry
43. Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery
44. Supplement to: Effect of platelet inhibition with cangrelor during PCI on ischemic events.
45. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
46. Clopidogrel with or without omeprazole in coronary artery disease.
47. Intravenous platelet blockade with cangrelor during PCI
48. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome
49. ESC/ESH guideline-recommended age categories and intensive blood pressure management in high-risk adults: insights from SPRINT
50. Assessment of platelet inhibition and its stability during aspirin and clopidogrel treatment: PB 4.27–2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.